Cofactor Genomics reports OncoPrism data

Create PDF

In clinical studies where OncoPrism was tuned to have the same sensitivity as PD-L1, Cofactor’s test reached 75 percent accuracy in predicting responders to immune checkpoint inhibitors compared with 42 pecent accuracy for PD-L1, according to a Cofactor news release. The company says these interim results from nine health care systems show that at similar sensitivity, OncoPrism has greater specificity and continues to be superior to single-analyte approaches like PD-L1.

Cofactor Genomics, 888-602-0448